A Comparative Study of the Pharmacokinetics of Astragaloside IV in Normal and Diabetic Nephropathic Rats

Qun Wang,Ya Shi,Zipeng Gong,Yonglin Wang,Yongjun Li,Aimin Wang
2019-01-01
Latin american journal of pharmacy
Abstract:We sought to compare the pharmacokinetic behavior of astragaloside IV in normal and diabetic nephropathic rats and expound any differences in the context of physiological and pathological states. A diabetic nephropathic rat model was established by intravenous administration of streptozotocin (45 mg/kg). Assessment conformation of diabetic nephropathy (DN) was done by assessing the levels of blood glucose, serum creatinine, blood urea nitrogen (BUN), and 24 h urinary albumin. A single dose of astragaloside IV (8 mg/kg) was then given intravenously after the conformation of diabetic nephropathy and pharmacokinetic parameters such as mean residence lime (MRT), the area under concentration-time curve (AUC), time to reach C-max (T-max) half-life of elimination (T-1/2), and plasma clearance (CLZ/F) via high performance liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) were deter- mined. There was a significant difference in the AUC((0-t)), AUC((0-infinity)), T-1/2, MRT(0-t), MRT(0-infinity), CLZ/F, and V-Z/F of astragaloside IV observed in the diabetic nephropathic rats versus normal rats (p < 0.01). The bioavailability of astragaloside IV in diabetic nephropathic rats was significantly improved.
What problem does this paper attempt to address?